Infantile hemangiomas are characterized by early and rapid growth that can subside spontaneously and are true hemangiomas. Female infants outnumber male infants (5:1). Most of them are seen as a small red spot or patch on the skin after birth, and then rapidly increase in size, thicken and rise above the skin, becoming bright red with an unsmooth surface, resembling a strawberry, also known as strawberry hemangioma. It is also called strawberry hemangioma. Part of it shows as a rapidly growing mass under the skin. It continues to grow for 6 to 8 months, and after a resting period of 1 to 2 months, it mostly enters the receding period at 8 to 12 months. According to our clinical observation for many years, it usually does not recede until about 8 years old, and one-third of the peak volume of the receding hemangioma body, i.e., two-thirds of the residual volume, and the probability of receding is 80%. The signs of regression are a change from bright red to dark red or purplish red, and a decrease in tension of the tumor. It usually starts in the center and gradually fades to the periphery. Approximately 70% of hemangiomas that resolve spontaneously have residual skin changes, such as grayish or dilated capillaries, loose, thickened or scarred skin. Some giant infantile hemangiomas may also be combined with thrombocytopenia and purpura, known as the kasabach-merritt phenomenon, which is prone to bleeding and can occur in the cranial and gastrointestinal tracts, resulting in a life-threatening mortality rate of about 40%, hence the term dangerous hemangioma. Because of the rapid growth and expansion of hemangioma in early stage, it has the tendency to expand to normal tissues and involve normal skin tissues; the rich blood supply of hemangioma leads to local tissue hypertrophy, and local plastic repair is still needed after hemangioma subsides; the skin infiltrated by hemangioma is still different from normal skin color even if hemangioma subsides; about 10-30% of hemangiomas do not completely subside and need further treatment. According to our clinical treatment effect and experience, we believe that appropriate interventional treatment should be carried out in the early stage (proliferative stage) to inhibit its rapid growth and make it shift to the stable and receding stage, which is conducive to controlling the development of hemangioma in the early stage and reducing the complications in the later stage, and can also reduce the psychological and spiritual stress and fear of the children and parents. In clinical work, it is found that many damages of infant hemangioma do not come from the lesion itself, but often from overly aggressive treatment. In the past, cases treated with major surgery, freezing, isotopes, radiation, sclerotherapy, etc. were often not satisfactory as confirmed by long-term follow-up. Therefore, the choice of treatment for infantile hemangiomas should be based on the basic principle that the total effect of treatment should not be worse than the natural regression of the hemangioma. First of all, overly strong treatment methods should be avoided (e.g. freezing to produce ulceration and scars, radiation therapy to cause local tissue developmental disorders and higher incidence of malignant tumors), and surgical treatment can be considered for small scope, or in the respiratory tract due to life-threatening, in the ear canal that will affect voice development, or in the eye that will affect vision. Oral hormone (4-5mg/kg/d) has about 30% clear efficacy on hemangioma, but the amount of hormone reaching the local area of hemangioma is small, and there are more side effects of hormone, and the growth and development of infants and children are affected during the use of hormone, therefore, mainly for those who have large area of hemangioma and infiltrate important tissues and organs which are difficult to be treated by surgery or injection, systemic hormone treatment can be considered. However, foreign scholars recommend taking a low dose (2-3mg/kg/d) for 2 weeks, and then reducing the dose every 2-4 weeks for 10-11 months if it is effective, which is reported to have significantly less side effects than a high dose (5mg/kg/d). For superficial hemangiomas, the 585 pulsed dye laser can be used because of its superficial location without involving deeper tissues. We recommend local hemangioma interstitial injection (method: 0.5 ml of Depo-Provera, 5 mg of methotrexate mixed with 2 ml of 1% lidocaine and injected directly (no blood is drawn back) into the hemangioma interstitial), which is safe and effective with few side effects. If the growth of hemangioma is not controlled, the injection treatment will be repeated after 1.5 months. The hormone used is Depo-Provera, which contains betamethasone dipropionate and betamethasone sodium phosphate, and has a rapid onset and long-lasting effect (about 4 weeks). Methotrexate is an anti-folate antitumor agent that acts mainly through competitive inhibition of dihydrofolate reductase. It acts more specifically in the DNA synthesis phase, and cells with high growth ratios, such as the vascular endothelial cells of hemangioma, are more sensitive to the effect of methotrexate and can inhibit their proliferation with fewer side effects. The combination of hormones and methotrexate has a milder effect and is able to inhibit the growth of hemangiomas without producing skin necrosis. Most infantile hemangiomas can be treated with local injections to reach the stage of converting hemangioma growth control to stable regression. For deep or mixed hemangiomas, we use embolization sclerotherapy combined with hormone therapy injections. We noticed that the high local temperature of hemangioma, MRI showed the phenomenon of flowing emptying of blood vessels and puncture retraction of bright red blood, suggesting that hemangioma has abundant micro arteriovenous fistula, which may be one of the driving forces of hemangioma growth and may also be the reason for the poor effect of hormone systemic use or local injection. Therefore, for children with deep hemangioma, larger hemangioma, or combined KM phenomenon, we first embolize the micro arteriovenous fistula of hemangioma, and then inject hormone. Embolization of the micro arteriovenous fistula of the hemangioma reduces the abnormal passage of the hemangioma, which may eliminate the dynamic effect of high pressure and rapid blood flow to accelerate the growth of the hemangioma; allowing the hormone to stay in the lumen of the hemangioma strengthens the effective and long-lasting effect of hormone Depo-Provera. Thus, embolization sclerosis combined with hormone injection therapy can reduce the abnormal channels of hemangioma, while allowing the hormone to have a long-lasting effect locally and reducing the side effects of hormone flow to the whole body. Treatment of the Kasabach CMerritt phenomenon is difficult. Patients with these hemangiomas have severe progressive platelet depletion and exhibit a generalized bleeding tendency, often with rapid onset and progressive worsening of symptoms over a short period of time. The main treatment method is embolization and sclerosis combined with hormone injection as described above. After treatment, most of the platelets return to normal rapidly, and some return to normal later, and the tumor gradually shrinks and does not recur. For regressive hemangioma, the aim of treatment is to improve the appearance, targeting skin atrophy, capillary dilation and excessive deposition of fibrofatty tissue. Laser is effective for some capillary dilation. Excessive fibrofatty tissue may be considered for surgical excision and atrophic skin may be surgically corrected. The timing of surgery may be chosen to be performed before school entry or much later. For the latest treatment, we use low-dose propranolol (1 mg/kg/d) (essentially a complete replacement for oral hormone therapy) in combination with interstitial injections or bolus sclerotherapy, or with bolus sclerotherapy injections with good results. The first day after treatment the tumor begins to darken and lighten in color, the tumor tone decreases, and the volume begins to shrink, with the most dramatic changes occurring about one week after treatment. Interstitial injection or embolization sclerotherapy combined with oral propranolol can rapidly control the rapid growth of the tumor, which is less invasive, reliable, safe, and has good morphological and functional recovery, and is the treatment of choice for severe or special areas of infantile hemangioma.